Ask AI
Targeting RAS in PDAC

CE / CME

Novel RAS-Targeted Therapies for Pancreatic Ductal Adenocarcinoma

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 15, 2026

Expiration: October 14, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Christopher Lieu, MD, FASCO, and Wungki Park, MD, MS, discuss the evolving field of RAS-targeted therapies for metastatic pancreatic ductal adenocarcinoma (PDAC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with pancreatic cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

Which of the following KRAS mutations could be targeted by the investigational agent daraxonrasib?

Which of the following investigational KRAS-targeted agents is being assessed in an ongoing phase III trial in combination with chemotherapy as first-line therapy compared with standard of care chemotherapy alone in patients with advanced pancreatic cancer?

Which of the following has been reported from early-stage trials of investigational RAS(ON)-targeted therapies?